Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 symbols : Mtcr save search
Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis
Published: 2022-12-16 (Crawled : 18:00) - biospace.com/
EQ | $1.85 0.0% 93K
|
Health Technology
|
| O: -0.33%
H: 0.76%
C: -3.44%
study phase 2 ulcerative colitis
Metacrine Reports Topline Results for MET409 Phase 2a Combination Trial In Patients with Type 2 Diabetes and NASH
Published: 2021-11-15 (Crawled : 18:00) - metacrine.com
MTCR | $0.5814 -5.14% 84K
|
Health Technology
|
| O: 1.6%
H: 2.36%
C: -0.79%
diabetes phase 2 results topline nash trial phase 2b
Metacrine Reports Topline Results for MET409 Phase 2a Combination Trial In Patients with Type 2 Diabetes and NASH
Published: 2021-11-02 (Crawled : 18:00) - biospace.com/
MTCR | $0.5814 -5.14% 84K
|
Health Technology
|
| O: 0.0%
H: 4.48%
C: -4.23%
diabetes phase 2 results topline nash trial phase 2b
Metacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With Nash
Published: 2021-09-09 (Crawled : 12:15) - globenewswire.com
MTCR | $0.5814 -5.14% 84K
|
Health Technology
|
| O: 1.01%
H: 4.0%
C: 0.0%
phase 2 nash trial met642 phase 2b enroll
Metacrine Achieves Full Enrollment for MET409 Phase 2a Combination Trial in Patients With Type 2 Diabetes and NASH
Published: 2021-06-02 (Crawled : 12:15) - globenewswire.com
MTCR | $0.5814 -5.14% 84K
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -2.67%
diabetes phase 2 nash trial phase 2b enroll
Metacrine Achieves Enrollment Target for MET642 Phase 2a Trial Interim Analysis
Published: 2021-05-18 (Crawled : 12:15) - globenewswire.com
MTCR | $0.5814 -5.14% 84K
|
Health Technology
|
| O: 0.0%
H: 3.01%
C: 0.27%
phase 2 trial met642 phase 2b enroll
Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at the 2021 NASH-TAG Conference
Published: 2021-03-11 (Crawled : 12:00) - globenewswire.com
MTCR | $0.5814 -5.14% 84K
|
Health Technology
|
| O: 1.97%
H: 4.55%
C: -5.0%
phase 1 results trial phase 3 phase 2 met642 nash
Metacrine Initiates Phase 2a Trial of MET642 for the Treatment of Patients with NASHOn-track for Interim Analysis Readout in the Fourth Quarter of 2021
Published: 2021-03-09 (Crawled : 14:23) - biospace.com/
MTCR | $0.5814 -5.14% 84K
|
Health Technology
|
| O: 1.83%
H: 6.74%
C: 2.25%
treatment phase 2 trial met642 phase 2b
Metacrine Initiates Phase 2a Trial of MET642 for the Treatment of Patients with NASH
Published: 2021-03-09 (Crawled : 12:00) - globenewswire.com
MTCR | $0.5814 -5.14% 84K
|
Health Technology
|
| O: 1.83%
H: 6.74%
C: 2.25%
treatment phase 2 trial met642 nash phase 2b
Metacrine Reports Positive Results from Phase 1 Trial of MET642
Published: 2020-12-17 (Crawled : 12:01) - globenewswire.com
MTCR | $0.5814 -5.14% 84K
|
Health Technology
|
| O: 4.18%
H: 2.64%
C: -5.19%
results positive results positive trial phase 3 phase 1 phase 2 met642
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.